Investing.comCodex · 实盘不做把握 7/10
北京时间·🕒 发布 04:40:30时区推断·⟳ 抓取 04:41:04·⚡ 决策 08-04 05:46:50 +1h05m·84.8 天前
Apnimed完成2.208亿美元IPO融资并于7月31日开始交易
公司以每股16.00美元发行1380万股、募资2.208亿美元，但本条是IPO交割完成的例行确认。
📄 原文Investing.com↗ 原文
Apnimed closes $220.8 million IPO on Nasdaq
Dow posts first record close in nearly a month as stocks rally to kick off August CAMBRIDGE, Mass. - Apnimed Inc. (NASD…
不做 Apnimed（APMD.US）
IPO已于7月31日开始交易，当前只是2.208亿美元发行交割完成的例行确认，缺少新的可交易边际。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 medium · price-in 风险 high ↗
关键理由
- 公司以每股16.00美元发行1380万股、募资2.208亿美元，但本条是IPO交割完成的例行确认。
主要风险
- 股票已于7月31日开始交易，交割公告通常不提供新的短线业绩或监管催化。
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 1,602 字
Dow posts first record close in nearly a month as stocks rally to kick off August
CAMBRIDGE, Mass. - Apnimed Inc. (NASDAQ:APMD) announced today the closing of its initial public offering of 13,800,000 shares of common stock at $16.00 per share, according to a press release statement.
The offering included the full exercise of the underwriters’ overallotment option to purchase 1,800,000 additional shares. The gross proceeds before deducting underwriting discounts, commissions and offering expenses totaled $220.8 million. All shares were offered by the company.
Apnimed’s common stock began trading on the Nasdaq Global Select Market on July 31 under the ticker symbol APMD.
BofA Securities, Evercore ISI, Cantor and LifeSci Capital served as joint book-running managers for the offering.
The company is a clinical pharmaceutical company focused on developing oral therapies for sleep-related breathing diseases. Apnimed is advancing AD109, a product candidate designed to improve oxygenation in individuals with obstructive sleep apnea. AD109 has completed two Phase 3 clinical trials for the treatment of mild, moderate and severe obstructive sleep apnea.
The company’s New Drug Application for AD109 has been assigned a Prescription Drug User Fee Act goal date of February 28, 2027.
Registration statements relating to the initial public offering were filed with the Securities and Exchange Commission and became effective on July 30.
The company is based in Cambridge, Massachusetts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
CAMBRIDGE, Mass. - Apnimed Inc. (NASDAQ:APMD) announced today the closing of its initial public offering of 13,800,000 shares of common stock at $16.00 per share, according to a press release statement.
The offering included the full exercise of the underwriters’ overallotment option to purchase 1,800,000 additional shares. The gross proceeds before deducting underwriting discounts, commissions and offering expenses totaled $220.8 million. All shares were offered by the company.
Apnimed’s common stock began trading on the Nasdaq Global Select Market on July 31 under the ticker symbol APMD.
BofA Securities, Evercore ISI, Cantor and LifeSci Capital served as joint book-running managers for the offering.
The company is a clinical pharmaceutical company focused on developing oral therapies for sleep-related breathing diseases. Apnimed is advancing AD109, a product candidate designed to improve oxygenation in individuals with obstructive sleep apnea. AD109 has completed two Phase 3 clinical trials for the treatment of mild, moderate and severe obstructive sleep apnea.
The company’s New Drug Application for AD109 has been assigned a Prescription Drug User Fee Act goal date of February 28, 2027.
Registration statements relating to the initial public offering were filed with the Securities and Exchange Commission and became effective on July 30.
The company is based in Cambridge, Massachusetts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。